Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.
Cure TV
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE magazine, shares the latest research in metastatic breast cancer, including targeted drugs being tested in early-phase studies that appear promising, including the PARP inhibitor veliparib, the CDK4/6 inhibitor palbociclib and the anti-angiogenesis drug trametinib.
Advertisement
